

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

**SUTRO BIOPHARMA, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**47-0926186**  
(I.R.S. Employer  
Identification No.)

**111 Oyster Point Blvd.**  
**South San Francisco, California, 94080**  
**(650) 881-6500**  
(Address of Principal Executive Offices) (Zip Code)

**2018 Equity Incentive Plan**  
(Full Title of the Plans)

**Jane Chung, R.Ph.**  
**Chief Executive Officer**  
**Sutro Biopharma, Inc.**  
**111 Oyster Point Blvd.**  
**South San Francisco, CA 94080**  
(Name and Address of Agent for Service)

**(650) 881-6500**  
(Telephone Number, including area code, of agent for service)

*Please send copies of all communications to:*

**Amanda L. Rose, Esq.**  
**Ryan Mitteness, Esq.**  
**Fenwick & West LLP**  
**401 Union Street**  
  
**5th Floor**  
**Seattle, Washington 98101**  
**(206) 389-4510**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**REGISTRATION OF ADDITIONAL SHARES  
PURSUANT TO GENERAL INSTRUCTION E**

Sutro Biopharma, Inc. (the “*Registrant*”) is filing this Registration Statement with the Securities and Exchange Commission (the “*Commission*”) to register 429,215 additional shares of common stock available for issuance under the Registrant’s Equity Incentive Plan (the “2018 EIP”), pursuant to the provision of the 2018 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance.

In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2018 EIP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on [September 27, 2018](#) (Registration No. 333-227551), [April 1, 2019](#) (Registration No. 333-230641), [March 16, 2020](#) (Registration No. 333-237202), [March 18, 2021](#) (Registration No. 333-254456), [March 1, 2022](#) (Registration No. 333-263113), [February 27, 2023](#) (Registration No. 333-270055), [February 27, 2024](#) (Registration No. 333-277404) and [February 27, 2025](#) (Registration No. 333-285346) to the extent not superseded hereby.

---

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”) are incorporated herein by reference:

the Registrant’s Annual Report on [Form 10-K](#) for the year ended December 31, 2025, filed with the Commission on March 23, 2026 pursuant to Section 13 of the Exchange Act;

all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

the description of the Registrant’s common stock contained in the Registrant’s registration statement on [Form 8-A](#) (File No. 001-38662) filed on September 18, 2018 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

**Item 8. Exhibits.**

Exhibit Number	Exhibit Description	Incorporated by Reference				Filed Herewith
		Form	File No.	Exhibit	Filing Date	
4.1	<a href="#">Amended and Restated Certificate of Incorporation of Sutro Biopharma, Inc., as amended.</a>	10-K	001-38662	3.1	03/23/2026	
4.2	<a href="#">Amended and Restated Bylaws of the Registrant.</a>	8-K	001-38662	3.1	02/24/2023	
4.3	<a href="#">Form of Registrant’s Common Stock Certificate.</a>	S-1/A	333-227103	4.1	09/17/2018	
5.1	<a href="#">Opinion and Consent of Fenwick &amp; West LLP.</a>					X
23.1	<a href="#">Consent of independent registered public accounting firm.</a>					X
23.2	<a href="#">Consent of Fenwick &amp; West LLP (contained in Exhibit 5.1).</a>					X
24.1	<a href="#">Power of Attorney (included on signature page of this Registration Statement).</a>					X
99.1	<a href="#">2018 Equity Incentive Plan.</a>	S-1/A	333-227103	10.4	09/17/2018	
99.2	<a href="#">Amended Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan.</a>	10-Q	001-38662	10.1	11/8/2019	
99.3	<a href="#">Amended Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan.</a>	10-Q	001-38662	10.2	11/8/2019	
107.1	<a href="#">Calculation of Registration Fees.</a>					X

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 23rd day of March, 2026.

### **SUTRO BIOPHARMA, INC.**

By: /s/ Jane Chung  
Jane Chung  
Chief Executive Officer and Director

---

## POWER OF ATTORNEY

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints Jane Chung and Gregory Chow, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Jane Chung</u> Jane Chung	Chief Executive Officer and Director (Principal Executive Officer)	March 23, 2026
<u>/s/ Gregory Chow</u> Gregory Chow	Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)	March 23, 2026
<u>/s/ Connie Matsui</u> Connie Matsui	Director, Chair	March 23, 2026
<u>/s/ Michael Dybbs, Ph.D.</u> Michael Dybbs, Ph.D.	Director	March 23, 2026
<u>/s/ Heidi Hunter</u> Heidi Hunter	Director	March 23, 2026
<u>/s/ Sukhi Jagpal</u> Sukhi Jagpal	Director	March 23, 2026
<u>/s/ Joseph M. Lobacki</u> Joseph M. Lobacki	Director	March 23, 2026
<u>/s/ James Panek</u> James Panek	Director	March 23, 2026
<u>/s/ Daniel H. Petree</u> Daniel H. Petree	Director	March 23, 2026
<u>/s/ Jon Wigginton, M.D.</u> Jon Wigginton, M.D.	Director	March 23, 2026

---



One Front Street  
33<sup>rd</sup> Floor  
San Francisco, CA 94111

415.875.2300  
Fenwick.com

March 23, 2026

Sutro Biopharma, Inc.  
111 Oyster Point Blvd.  
South San Francisco, California 94080

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

As counsel to Sutro Biopharma, Inc., a Delaware corporation (the “**Company**”), we have examined the Registration Statement on Form S-8 (the “**Registration Statement**”) to be filed by the Company with the Securities and Exchange Commission (the “**Commission**”) on or about March 23, 2026 in connection with the registration under the Securities Act of 1933, as amended (the “**Securities Act**”), of an aggregate of 429,215 shares (the “**Shares**”) of the Company’s Common Stock, \$0.001 par value per share (the “**Common Stock**”), that are subject to issuance by the Company upon the exercise or settlement of awards granted or to be granted under the 2018 Equity Incentive Plan.

As to matters of fact relevant to the opinions rendered herein, we have examined such documents, certificates and other instruments which we have deemed necessary or advisable, including a certificate addressed to us and dated the date hereof executed by the Company. We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties or to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of the Company or the rendering of the opinion set forth below. We have not considered parol evidence in connection with any of the agreements or instruments reviewed by us in connection with this letter.

In our examination of documents for purposes of this letter, we have assumed, and express no opinion as to, the genuineness and authenticity of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, that each document is what it purports to be, the conformity to originals of all documents submitted to us as copies or facsimile copies, the absence of any termination, modification or waiver of or amendment to any document reviewed by us (other than as has been disclosed to us), the legal competence or capacity of all persons or entities (other than the Company) executing the same and (other than the Company) the due authorization, execution and delivery of all documents by each party thereto. We have also assumed the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System (“**EDGAR**”), except for required EDGAR formatting changes, to physical copies submitted for our examination.

---

The opinions in this letter are limited to the existing General Corporation Law of the State of Delaware now in effect. We express no opinion with respect to any other laws.

Based upon, and subject to, the foregoing, it is our opinion that the Shares, when issued and sold by the Company in accordance with the terms (including, without limitation, payment and authorization provisions) of the applicable Plan and the applicable form of award agreement thereunder, against the Company's receipt of payment therefor (in an amount and type of consideration not less than the par value per Share), and duly registered on the books of the transfer agent and registrar for the Shares in the name or on behalf of the holders thereof, will be validly issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the prospectuses constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

This opinion is intended solely for your use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.

Very truly yours,

/s/ Fenwick & West LLP

**FENWICK & WEST LLP**

---

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement on Form S-8 pertaining to the 2018 Equity Incentive Plan of Sutro Biopharma, Inc. of our report dated March 23, 2026, with respect to the financial statements of Sutro Biopharma, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California  
March 23, 2026

---

Calculation of Filing Fee Tables

Form S-8 (Form Type)

Sutro Biopharma, Inc.

(Exact Name of Registrant as Specified in its Charter)

Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1 Equity	Common stock, par value \$0.001 per share	Rule 457(c) and Rule 457(h)	429,215	\$21.42	\$9,193,785	0.0001381	\$1,270
			Total Offering Amounts:		\$9,193,785	N/A	\$1,270
			Total Fee Offsets:				\$0
			Net Fee Due:				1,270

Offering Note

Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, par value \$0.001 per share (“Common Stock”), that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Sutro Biopharma, Inc.’s (the “Registrant”) Common Stock.

1

- (1) Represents additional shares of Common Stock to be registered and available for grant under the Registrant’s 2018 Equity Incentive Plan (the “2018 EIP”) resulting from the annual 5% automatic increase in the number of authorized Shares available for issuance under the 2018 EIP.
- (2) Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per Share of \$21.42 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Global Market on March 19, 2026.